489 related articles for article (PubMed ID: 33726504)
21. The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR; Coleman RL; González-Martín A; Moore KN; Colombo N; Ray-Coquard I; Pignata S
Ann Oncol; 2020 Sep; 31(9):1148-1159. PubMed ID: 32569725
[TBL] [Abstract][Full Text] [Related]
22. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
23. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643
[TBL] [Abstract][Full Text] [Related]
24. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
Vanacker H; Romeo C; Ray-Coquard I
Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
[TBL] [Abstract][Full Text] [Related]
25. Latest clinical evidence of maintenance therapy in ovarian cancer.
Walsh CS
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):15-21. PubMed ID: 31833941
[TBL] [Abstract][Full Text] [Related]
26. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
27. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
[TBL] [Abstract][Full Text] [Related]
28. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
29. PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer.
Giannini A; Di Dio C; Di Donato V; D'oria O; Salerno MG; Capalbo G; Cuccu I; Perniola G; Muzii L; Bogani G
Am J Clin Oncol; 2023 Sep; 46(9):414-419. PubMed ID: 37314974
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
Moore KN; Pothuri B
Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
[TBL] [Abstract][Full Text] [Related]
31. Newly diagnosed ovarian cancer: Which first-line treatment?
Lorusso D; Ceni V; Daniele G; Salutari V; Pietragalla A; Muratore M; Nero C; Ciccarone F; Scambia G
Cancer Treat Rev; 2020 Dec; 91():102111. PubMed ID: 33068886
[TBL] [Abstract][Full Text] [Related]
32. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
Pham MM; Hinchcliff E; Avila M; Westin SN
Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
[TBL] [Abstract][Full Text] [Related]
33. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
34. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.
Miller RE
Cancer J; 2021 Nov-Dec 01; 27(6):506-510. PubMed ID: 34904814
[TBL] [Abstract][Full Text] [Related]
36. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Mirza MR; Pignata S; Ledermann JA
Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
[TBL] [Abstract][Full Text] [Related]
37. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
Bahena-González A; Toledo-Leyva A; Gallardo-Rincón D
Chin Clin Oncol; 2020 Aug; 9(4):51. PubMed ID: 32819110
[TBL] [Abstract][Full Text] [Related]
40. Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.
Wright KM
Oncology (Williston Park); 2020 May; 34(5):175. PubMed ID: 32644177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
